Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

73.77
+0.15000.20%
Post-market: 73.770.00000.00%19:30 EDT
Volume:1.72M
Turnover:127.93M
Market Cap:10.26B
PE:-10.27
High:75.98
Open:74.66
Low:73.50
Close:73.62
52wk High:88.31
52wk Low:47.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:1.14
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-59.12
PE(LYR):-11.28

Loading ...

Cytokinetics Insider Move Sparks Fresh Investor Buzz

TIPRANKS
·
Sep 12

Cytokinetics Director Robert E. Landry Sells 1,000 Common Shares Worth $74,660

Reuters
·
Sep 12

Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says

MT Newswires Live
·
Sep 11

Cytokinetics EVP R&D Malik Fady Ibraham Disposes of 3,500 Common Shares for $264,110

Reuters
·
Sep 09

Movement Alert|Cytokinetics Rises 5.1% in Regular Trading, ESC Congress Data and Label Expansion Plans Continue to Boost Sentiment

Market Focus
·
Sep 09

Cytokinetics Management to Join Citi BioPharma Investor Conference Fireside Chat

Reuters
·
Sep 03

High-Profile Insider Move Shakes Up Cytokinetics Watchers

TIPRANKS
·
Sep 02

Cytokinetics CEO Robert I. Blum Disposes of $526,800 in Common Shares

Reuters
·
Sep 01

Evercore ISI Remains a Buy on Cytokinetics (CYTK)

TIPRANKS
·
Aug 31

Cytokinetics Price Target Maintained with a $140.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Cytokinetics (CYTK) Extends Aficamten Phase 3 Data, Is It Still 33% Below Fair Value?

Simply Wall St.
·
Aug 31

RBC Capital Sticks to Their Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
Aug 31

Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM

TIPRANKS
·
Aug 31

Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?

Simply Wall St.
·
Aug 30

Cytokinetics Posts MAPLE-HCM Presentation on Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy

Reuters
·
Aug 29

Cytokinetics Announces Additional Results from Acacia-HCM and Maple-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (Esc) Congress 2026

THOMSON REUTERS
·
Aug 29

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

GlobeNewswire
·
Aug 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 29

Movement Alert|Cytokinetics Intraday Decline 6.03%, Shares Retreat Despite Positive Phase 3 Trial Data Presentation at ESC Congress

Market Focus
·
Aug 28

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28